- In July 2024, DELFI Diagnostics announced that it has secured an equity investment from the Merck Global Health Innovation Fund. This strategic funding will accelerate the development of DELFI’s AI-driven fragmentomics platform designed for advanced cancer screening. The collaboration is focused on enhancing diagnostic capabilities and advancing the methodologies used for more accurate cancer detection. This partnership aligns with the growing trend towards AI-powered diagnostic solutions and precision oncology. The investment will support the development of cutting-edge technologies that are poised to revolutionize early cancer detection, driving innovation in the market and expanding the availability of advanced diagnostic tools globally
- In May 2024, Quest Diagnostics revealed the separation of PathAI’s digital pathology laboratory as part of a strategic initiative to deepen its focus on artificial intelligence (AI) integration. This move is designed to expedite the adoption of AI technologies within the company's operations, with the goal of enhancing its digital pathology capabilities and improving diagnostic accuracy. This development highlights the growing trend of incorporating AI-driven solutions into diagnostic workflows. By advancing its digital pathology offerings, Quest Diagnostics is positioning itself at the forefront of the shift toward more precise and efficient cancer detection
- In February 2023, F. Hoffmann-La Roche announced the expansion of its collaboration with Janssen to further advance personalized healthcare initiatives. This strengthened partnership will focus on the development of companion diagnostics, with the goal of improving treatment outcomes for patients by enabling more precise and tailored therapeutic approaches. This collaboration underscores the increasing shift towards precision oncology and the growing importance of companion diagnostics in improving cancer treatment
- In November 2023, Abbott received FDA approval for its HPV test, developed for use with the Alinity m platform. This diagnostic tool is designed for primary screening of HPV and detection of high-risk HPV types linked to cancer, particularly cervical cancer. This approval significantly strengthens Abbott’s portfolio in cervical cancer prevention and diagnosis, aligning with the growing demand for advanced screening solutions in the global cancer diagnostics market
- In 2022, Precipio, Inc. entered into a distribution agreement for its HemeScreen product with a prominent distribution partner in the U.S. The company is strategically pursuing an expansive growth plan for HemeScreen, targeting physician-owned laboratories, national and regional hospital networks, and reference laboratories. This move emphasizes the increasing demand for advanced diagnostic tools that enable more precise and efficient detection of hematologic cancers
